-
2023-506365-64-00
5
2020-10-16
Deleterious Germline or Somatic Homologous Recombination Repair (HRR)
-
2024-514703-34-00
5
2020-09-08
Thromboembolic event
-
2023-505812-39-00
5
2020-08-28
HR+/HER2-Negative Locally Advanced or Metastatic Breast cancer with PI
-
2023-505830-89-00
6
2020-08-05
metastatic castrate resistant prostate cancer (mCRPC)
-
2024-515379-36-00
9
2020-08-04
Metastatic pancreatic ductal adenocarcinoma
-
2024-513005-31-00
5
2020-06-11
Patients with untreated metastatic Estrogen Receptor positive (ER+), H
-
2022-501974-21-00
5
2020-04-01
Prevention of oral persistent infection caused by any of the human pap
-
2023-506782-56-00
5
2020-03-10
RET-Mutant Medullary Thyroid Cancer
-
2024-511653-22-00
5
2020-02-12
Cutaneous Squamous Cell Carcinoma (CSCC)
-
2024-518069-89-00
4
2020-02-03
Patients with solid cancers
-
2024-512269-14-00
5
2020-01-27
GIant cell Arteritis
-
2022-501531-16-00
5
2020-01-24
esophageal carcinoma
-
2023-510248-19-00
5
2020-01-21
Eosinophilic Granulomatosis with Polyangiitis (EGPA)
-
2023-509908-15-00
10
2020-01-20
Mantle Cell Lymphoma
-
2023-508635-31-00
5
2019-12-03
Hepatocellular Carcinoma
-
2024-514829-36-00
5
2019-12-02
High-risk biochemically-relapsed prostate adenocarcinoma following rad
-
2024-511849-19-00
4
2019-10-17
Luminal B Breast Cancer
-
2024-514088-25-00
5
2019-10-07
Multiple Myeloma
-
2023-507886-25-00
4
2019-09-27
Previously untreated and symptomatic patients with histologically prov
-
2023-505321-14-00
10
2019-09-06
Warm Autoimmune Hemolytic Anemia
-
2024-516847-23-00
4
2019-08-27
ER-positive and HER2-negative metastatic or locally advanced breast ca
-
2023-507405-34-00
5
2019-08-07
First-line patients with advanced biliary tract cancers (BTC)
-
2024-515946-17-00
5
2019-07-22
Non Small Cell Lung Cancer
-
2024-514885-38-00
5
2019-07-11
severe forms of mucous membrane pemphigoid